Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Israel Galtes

Cardiovascular Disease Homestead, FL Medical Doctor

NPI 1457326746 CMS profile 202226

950 N Krome Ave, Suite 202, Homestead, FL 33030

Open in the dashboard

General payments

$47,011

580 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$282,999 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Israel Galtes of Homestead, FL is reported in the CMS Open Payments database as having received $47,011 across 580 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $282,999 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,282 58
2024 General $4,137 81
2023 General $20,747 102
2022 General $16,665 111
2021 General $2,166 103
2020 General $740 45
2019 General $1,275 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Israel Galtes
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Israel Galtes were reported at $1,282. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Israel Galtes Cardiovascular Disease median Middle half National median
2019 $1,275 $450 $127–$1,392 $163
2020 $740 $242 $77–$751 $114
2021 $2,166 $335 $101–$1,037 $132
2022 $16,665 $395 $121–$1,211 $149
2023 $20,747 $443 $136–$1,283 $160
2024 $4,137 $450 $136–$1,323 $164
2025 $1,282 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $36,825 55 payments
  2. AstraZeneca Pharmaceuticals LP $1,244 61 payments
  3. Pfizer Inc. $1,090 59 payments
  4. Janssen Pharmaceuticals, Inc $995 71 payments
  5. Amgen Inc. $888 57 payments
  6. Esperion Therapeutics, Inc. $713 31 payments
  7. Sanofi-Aventis U.S. LLC $623 33 payments
  8. Novartis Pharmaceuticals Corporation $616 36 payments
  9. Philips Electronics North America Corporation $432 24 payments
  10. E.R. Squibb & Sons, L.L.C. $417 21 payments
  11. Other $3,169 132 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $34,239 13 payments
  2. Food and Beverage $11,137 556 payments
  3. Travel and Lodging $1,590 7 payments
  4. Education $46 4 payments
Products named General payments · program years 2019–2025
  1. VERQUVO Cardiovascular $39,207 62 payments
  2. VERQUVO Cardiovascular $19,073 15 payments
  3. FARXIGA $1,015 51 payments
  4. XARELTO $995 71 payments
  5. Repatha $847 55 payments
  6. NEXLETOL $713 31 payments
  7. ELIQUIS $572 28 payments
  8. VYNDAQEL $541 31 payments
  9. (5044) MCOT $374 21 payments
  10. ENTRESTO $355 20 payments
  11. Other $6,127 281 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 71 drugs

Part D claims

8,220

Median for Cardiology: 2,533

Drug cost

$1,561,920

Median for Cardiology: $485,213

Branded share of claims

33.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 486 $395,576
Xarelto Rivaroxaban Brand 339 $255,292
Entresto Sacubitril/Valsartan Brand 278 $226,230
Multaq Dronedarone Hcl Brand 135 $146,205
Farxiga Dapagliflozin Propanediol Brand 188 $132,788
Repatha Sureclick Evolocumab Brand 139 $101,022
Verquvo Vericiguat Brand 78 $60,035
Praluent Pen Alirocumab Brand 75 $37,370
Nexlizet Bempedoic Acid/Ezetimibe Brand 73 $34,864
Brilinta Ticagrelor Brand 50 $24,347

The 10 drugs with the highest cost, of 71 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$157,282

Of which drugs: $393

Medicare patients

330

Average age 75

Services billed

1,783

182 women, 148 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 60%
Arthritis 56%
Diabetes 44%
Chronic kidney disease 44%
Heart failure 34%
Atrial fibrillation 34%
Depression 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 22 88 $392

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $2,383
$2,383 78 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $203
$203 188 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $139
$139 29 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $112
$112 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $97
$97 339 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

580 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record